![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/regenxbio-announces-expansion-of-affinity-duchenne-trial-to-include-a-new-cohort-of-younger-patients-302180017.html
https://www.contractpharma.com/contents/view_breaking-news/2024-06-12/regenxbio-updates-leadership-names-new-ceo/
https://www.prnewswire.com/news-releases/regenxbio-announces-lancet-publication-of-phase-iiia-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd-302102175.html
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-participate-cantor-fitzgeralds-virtual-dmd-and-other
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-participate-upcoming-investor-conferences-17
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-pricing-upsized-public-offering-common-stock
https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-302082085.html
https://www.prnewswire.com/news-releases/regenxbio-announces-new-positive-initial-efficacy-data-from-affinity-duchenne-trial-302079525.html
https://www.pharmaceutical-technology.com/projects/regenxbio-research-and-development-facility-maryland/
https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-event-to-discuss-new-interim-clinical-data-from-the-phase-iii-affinity-duchenne-trial-302076483.html